To evaluate the corrective potential of combined JAK2 and ERK1/2 inhibition in human MPN settings, we tested clinical isolates from JAK2V617F MPN patients including PMF, PV and ET. The gene discussed is JAK2; the disease is acquired polycythemia vera.